In vitro evaluation of 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines

Journal of Drug Targeting

Volumn 21, Issue 4, 2013, Pages 383-388

  Yurt Lambrecht, Fatma ^a   Durkan, Kübra ^a   Özgür, Aykut ^a,b   Gündüz, Cumhur ^a   Avci, Çiǧir Biray ^a   Susluer, Sunde Yilmaz ^a  

^a EGE UNIVERSITY   (Turkey)

^b GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

99mTc EDDA tricine HYNIC Q Litorin; Bombesin like peptide; HYNIC Q Litorin; Pancreatic tumor

Indexed keywords

BOMBESIN; CYSTEINE; ETHYLENEDIAMINE N,N' DIACETIC ACID HYDRAZINONICOTINAMIDE Q LITORIN 99M TC; GASTRIN RELEASING PEPTIDE RECEPTOR; LITORIN; RADIOISOTOPE; TRICINE HYDRAZINONICOTINAMIDE Q LITORIN 99M TC; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; ISOTOPE LABELING; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; CYSTEINE; EDETIC ACID; GLYCINE; HUMANS; HYDRAZINES; LIGANDS; MICE; NIACINAMIDE; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RECEPTORS, BOMBESIN;

EID: 84877128152     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.757772     Document Type: Article

References (31)

1. 99mTc via hydrazinonicotinamide: description of optimized radiolabeling conditions. J Radioanal Nucl Chem 2010;284:539-45.
2. Durkan K, Yurt Lambrecht F, Unak P. Investigation of radiophar-maceutical potential and labeling methods of bombesin like peptide: litorin with Tc-99m. Bioconjug Chem 2007;18:1516-20.
3. Okarvi SM. Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004;24:357-97.
4. 3]octreotide. Bioconjug Chem 1999;10:431-8.
5. Okarvi SM, Al-Jammaz I. Synthesis, radiolabeling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res 2003;23:2745-50.
6. Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002;57:749-63.
7. Chandra S, De K, Ganguly S, et al. Synthesis, radiolabeling and biological evaluation of a neutral tripeptide and its derivates for potential nuclear medicine applications. Peptides 2009;30: 2399-408.
8. Melendez-Alafort L, Maria Ramirez F, Ferro-Flores G, et al. Lys and Arg in UBI: a specific site for a stable Tc-99m complex. Nucl Med Biol 2003;30:605-15.
9. Langer M, Beck-Sickinger AG. Peptide as carrier for tumor diagnosis and treatment. Curr Med Chem AntiCancer Agents 2001;1:71-93.
10. 3 expression. Nucl Med Biol 2006;33:945-52.
11. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
12. Ferro-Flores G, Ramirez, FM, Melendez-Alafort L, Santos-Cuevas CL. Peptides for in vivo target-specific cancer imaging. Med Chem 2010;10:87-97.
13. Faintuch BL, Teodoro R, Duatti A, et al. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008;35:401-11.
14. Ohki-Hamazaki H, Iwabuchi M, Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol 2005;49:293-300.
15. 99mTc labeled bombesin derivative for tumor imaging. J Radioanal Nucl Chem 2010;283:181-7.
16. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumor imaging. Eur J Nucl Med 2002;30:247-58.
17. Pukala TL, Bowie JH, Maselli VM, et al. Host-defence peptides from the grandular secretions of amphibians: structure and activity. Nat Prod Rep 2006;23:368-93.
18. 99mTc-Labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine- based bifunctional chelating agent. Bioconjug Chem 1999;10:254-60.
19. 99mTc- bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003;30:1378-82.
20. Lin JT, Coy DH, Mantey SA, Jensen RT. Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors. Eur J Pharmacol 1995;294:55.
21. Rivier JE, Brown MR. Bombesin, bombesin analogs, and related peptides: effects on thermoregulation. Biochem 1978;17:1766-71.
22. 99mTc complexes of a HYNIC-conjugated cyclic RGDfk dimmer. Bioconjug Chem 2005;16:1580-8.
23. 99mTc. Appl Radiat Isot 2007;65:805-8.
24. 99mTc-HYNIC-peptide. Nucl Med Biol 2002; 29:107-13.
25. Uddin-Surfraz MB, King R, Mather SJ, et al. Technetium-binding in labeled HYNIC-peptide conjugates: role of coordinating amino acids. J Inorg Biochem 2009;103:971-7.
26. 0-diacetic acid), tricine, and nicotinic acid. Synth React Inorg M 2005;35:43-51.
27. 2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem 2008;19:1170-8.
28. 99mTc as a GRP receptor imaging agent, J Radioanal Nucl Chem 2011;288: 327-35.
29. 3]-bom-besin for imaging gastrin-releasing peptide receptor-positive tumors. Nucl Med Com 2006;27:371-6.
30. 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 2011;41:439-47.
31. 99mTechnetium- HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm 2011;8:1165-73.